This is (supposed to be) a reflective diary by a (not very) anonymous biomedical scientist who works somewhere in the south of England.
One day this diary may well be submitted to the Health and Care Professions Council as evidence of ongoing continual professional development....
Guidelines suggest that NK1RA agents are interchangeable. This article reports the first study comparing one NK1RA (oral NEPA [netupitant/palonosetron]) with another (aprepitant) in patients receiving chemotherapy.
Aaron Hata, MD, PhD, Alice Shaw, MD, PhD and Rebecca Heist, MD, MPH address the therapeutic landscape of MET-, ALK- and ROS1-driven lung cancers, including the role of the drivers in oncogenesis, a review of the latest advances in targeted therapies and drug resistance, and examination of the different approaches in next-generation sequencing.